Vertex Pharmaceuticals Incorporated (VRTX) Shares are Down -2.04%

Vertex Pharmaceuticals Incorporated (VRTX) : During the past 4 weeks, traders have been relatively bearish on Vertex Pharmaceuticals Incorporated (VRTX), hence the stock is down -7.02% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.53% relative to the S&P 500. The 4-week change in the price of the stock is -7.15% and the stock has fallen -2.04% in the past 1 week.

The stock has recorded a 20-day Moving Average of 4.11% and the 50-Day Moving Average is 0.96%.The 200 Day SMA reached 0.57%. Vertex Pharmaceuticals Incorporated has dropped 1.02% during the last 3-month period . Year-to-Date the stock performance stands at -24.41%.


Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): After opening at $94.76, the stock dipped to an intraday low of $93.6547 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $95.54 and the buying power remained strong till the end. The stock closed at $95.11 for the day, a gain of 0.38% for the day session. The total traded volume was 843,132. The stocks close on the previous trading day was $94.75.

Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.